Cartesian Therapeutics (RNAC) Other Non Operating Income (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Other Non Operating Income of -$3000.0 for Q1 2026, down 100.04% quarter-over-quarter from $7.5 million in Q4 2024.
Powered by 
Analysis
Cartesian Therapeutics (RNAC) Other Non Operating Income (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Other Non Operating Income for 11 consecutive years, with -$3000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income changed N/A year-over-year to -$3000.0; the TTM figure through Mar 2026 stood at -$3000.0 (down 100.04% YoY), while the FY2024 annual figure was $606000.0, up 100.41% from the prior year.
- Other Non Operating Income slipped to -$3000.0 in Q1 2026 per RNAC's latest filing, from $7.5 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $7.5 million in Q4 2024 and bottomed at -$149.6 million in Q4 2023.
- Historically, Other Non Operating Income has averaged -$12.4 million across 4 years, with a median of $12000.0 in 2022.
- Annual changes were most pronounced in 2023 — Other Non Operating Income plunged 84441.81% — and 2024, when it surged 8433.33%.
- Cartesian Therapeutics' Other Non Operating Income stood at -$177000.0 in 2022, then slumped by 84441.81% to -$149.6 million in 2023, then surged by 105.01% to $7.5 million in 2024, then slumped by 100.04% to -$3000.0 in 2026.
- Business Quant data shows RNAC's Other Non Operating Income at -$3000.0 in Q1 2026, $7.5 million in Q4 2024, and $250000.0 in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Cartesian Therapeutics | 272.57 Mn | 272.57 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 126,000.00 |
| Mar 31, 2026 | -3,000.00 |
| Dec 31, 2025 | -2.01 Mn |
| Jun 30, 2025 | -5,000.00 |
| Sep 30, 2024 | 250,000.00 |
| Jun 30, 2024 | 292,000.00 |
| Mar 31, 2024 | -6.89 Mn |
| Dec 31, 2023 | -150.35 Mn |
| Sep 30, 2023 | 253,000.00 |
| Jun 30, 2023 | 245,000.00 |
| Mar 31, 2023 | 255,000.00 |
| Dec 31, 2022 | 175,000.00 |
| Sep 30, 2022 | 15,000.00 |
| Jun 30, 2022 | -104,000.00 |
| Mar 31, 2022 | 154,000.00 |
| Sep 30, 2021 | 9,000.00 |
| Jun 30, 2021 | -14,000.00 |
| Mar 31, 2021 | 7,000.00 |
| Sep 30, 2020 | -461,000.00 |
| Jun 30, 2020 | 59,000.00 |